Context Therapeutics Inc.
CNTX
$0.753
-$0.02-2.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.79M | 1.88M | 1.70M | 1.85M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.31M | 18.70M | 3.09M | 3.82M | 6.93M |
| Operating Income | -4.31M | -18.70M | -3.09M | -3.82M | -6.93M |
| Income Before Tax | -3.34M | -17.46M | -2.25M | -3.67M | -6.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.34M | -17.46M | -2.25M | -3.67M | -6.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.34M | -17.46M | -2.25M | -3.67M | -6.77M |
| EBIT | -4.31M | -18.70M | -3.09M | -3.82M | -6.93M |
| EBITDA | -4.31M | -18.70M | -3.09M | -3.82M | -6.93M |
| EPS Basic | -0.04 | -0.22 | -0.04 | -0.23 | -0.42 |
| Normalized Basic EPS | -0.03 | -0.14 | -0.03 | -0.14 | -0.27 |
| EPS Diluted | -0.08 | -0.22 | -0.04 | -0.23 | -0.42 |
| Normalized Diluted EPS | -0.03 | -0.14 | -0.03 | -0.14 | -0.27 |
| Average Basic Shares Outstanding | 81.93M | 80.48M | 54.96M | 15.97M | 15.97M |
| Average Diluted Shares Outstanding | 81.93M | 80.48M | 54.96M | 15.97M | 15.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |